Combining chemotherapy and BRAF oncogene inhibitors is an effective strategy for fighting metastatic melanoma, the leading cause of death from skin cancer in the world. This has been demonstrated in a study by researchers ...
Jul 13, 2021
0
2
A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer ...
Apr 17, 2015
0
43
Researchers from the UNC Lineberger Comprehensive Cancer Center analyzed hundreds of melanoma samples to find out if two genetic mutations more commonly found in melanoma tumors were associated with lower survival rates in ...
Apr 13, 2015
0
5
A University of Colorado Cancer Center study published online this week in the journal Molecular Cancer Therapeutics reports anti-cancer activity in 10 out of 11 patient tumor samples grown in mice and treated with the experimental ...
Nov 11, 2014
0
0
The protein BRAF is a key player in the development of many different types of cancer, including melanoma. Scientists have known that BRAF becomes activated by growth factors and subsequently stimulates downstream proteins ...
Apr 24, 2019
0
8
Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma. A new study that assessed ctDNA in the blood of patients with BRAF wild-type (BRAF WT) stage III and IV ...
Oct 4, 2023
0
23
A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression ...
Jun 2, 2013
0
0
Two new experimental treatments against advanced melanoma have shown promise in keeping the deadly skin cancer at bay, according to research presented in the United States on Monday.
Jun 4, 2012
0
0
(HealthDay)—For patients with stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant dabrafenib plus trametinib results in increased survival without relapse or distant metastasis at five years, according ...
Sep 4, 2020
0
3
A collaboration of researchers, led by UCL and Great Ormond Street Hospital, have published successful results from a Phase II clinical trial for the treatment of BRAF mutated low-grade pediatric gliomas.
Nov 21, 2023
0
11
